Literature DB >> 33556239

Spatial Regulation of T-Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets.

Trixy Fang1, Jonatan Alvelid2, Joel Spratt1, Elena Ambrosetti1, Ilaria Testa2, Ana I Teixeira1.   

Abstract

Programmed Death-1 (PD-1) is a coinhibitory receptor expressed on activated T cells that suppresses T-cell signaling and effector functions. It has been previously shown that binding to its ligand PD-L1 induces a spatial reorganization of PD-1 receptors into microclusters on the cell membrane. However, the roles of the spatial organization of PD-L1 on PD-1 clustering and T-cell signaling have not been elucidated. Here, we used DNA origami flat sheets to display PD-L1 ligands at defined nanoscale distances and investigated their ability to inhibit T-cell activation in vitro. We found that DNA origami flat sheets modified with CD3 and CD28 activating antibodies (FS-α-CD3-CD28) induced robust T-cell activation. Co-treatment with flat sheets presenting PD-L1 ligands separated by ∼200 nm (FS-PD-L1-200), but not 13 nm (FS-PD-L1-13) or 40 nm (FS-PD-L1-40), caused an inhibition of T-cell signaling, which increased with increasing molar ratio of FS-PD-L1-200 to FS-α-CD3-CD28. Furthermore, FS-PD-L1-200 induced the formation of smaller PD-1 nanoclusters and caused a larger reduction in IL-2 expression compared to FS-PD-L1-13. Together, these findings suggest that the spatial organization of PD-L1 determines its ability to regulate T-cell signaling and may guide the development of future nanomedicine-based immunomodulatory therapies.

Entities:  

Keywords:  DNA nanotechnology; DNA origami; PD-1 receptor; cancer immunotherapy; nanoscale spatial distribution

Mesh:

Substances:

Year:  2021        PMID: 33556239      PMCID: PMC7905882          DOI: 10.1021/acsnano.0c10632

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  52 in total

1.  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

Authors:  Katarzyna Guzik; Krzysztof M Zak; Przemyslaw Grudnik; Katarzyna Magiera; Bogdan Musielak; Ricarda Törner; Lukasz Skalniak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  J Med Chem       Date:  2017-06-23       Impact factor: 7.446

2.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

3.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

5.  Improving T Cell Expansion with a Soft Touch.

Authors:  Lester H Lambert; Geraldine K E Goebrecht; Sarah E De Leo; Roddy S O'Connor; Selene Nunez-Cruz; Tai-De Li; Jinglun Yuan; Michael C Milone; Lance C Kam
Journal:  Nano Lett       Date:  2017-01-30       Impact factor: 11.189

6.  CD28 and CD3 have complementary roles in T-cell traction forces.

Authors:  Keenan T Bashour; Alexander Gondarenko; Haoqian Chen; Keyue Shen; Xin Liu; Morgan Huse; James C Hone; Lance C Kam
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

7.  Nanoscale ligand spacing influences receptor triggering in T cells and NK cells.

Authors:  Derfogail Delcassian; David Depoil; Dominika Rudnicka; Mengling Liu; Daniel M Davis; Michael L Dustin; Iain E Dunlop
Journal:  Nano Lett       Date:  2013-10-21       Impact factor: 11.189

8.  Spatial organization-dependent EphA2 transcriptional responses revealed by ligand nanocalipers.

Authors:  Toon Verheyen; Trixy Fang; Dominik Lindenhofer; Yang Wang; Karen Akopyan; Arne Lindqvist; Björn Högberg; Ana I Teixeira
Journal:  Nucleic Acids Res       Date:  2020-06-04       Impact factor: 16.971

9.  TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation.

Authors:  Björn F Lillemeier; Manuel A Mörtelmaier; Martin B Forstner; Johannes B Huppa; Jay T Groves; Mark M Davis
Journal:  Nat Immunol       Date:  2009-12-13       Impact factor: 25.606

10.  Role of nanoscale antigen organization on B-cell activation probed using DNA origami.

Authors:  Rémi Veneziano; Tyson J Moyer; Matthew B Stone; Eike-Christian Wamhoff; Benjamin J Read; Sayak Mukherjee; Tyson R Shepherd; Jayajit Das; William R Schief; Darrell J Irvine; Mark Bathe
Journal:  Nat Nanotechnol       Date:  2020-06-29       Impact factor: 40.523

View more
  3 in total

Review 1.  Pharmaceutical applications of framework nucleic acids.

Authors:  Liang Chen; Jie Zhang; Zhun Lin; Ziyan Zhang; Miao Mao; Jiacheng Wu; Qian Li; Yuanqing Zhang; Chunhai Fan
Journal:  Acta Pharm Sin B       Date:  2021-05-26       Impact factor: 11.413

2.  Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials.

Authors:  Alice Comberlato; Marianna M Koga; Simone Nüssing; Ian A Parish; Maartje M C Bastings
Journal:  Nano Lett       Date:  2022-03-10       Impact factor: 11.189

3.  Determinants of Ligand-Functionalized DNA Nanostructure-Cell Interactions.

Authors:  Glenn A O Cremers; Bas J H M Rosier; Ab Meijs; Nicholas B Tito; Sander M J van Duijnhoven; Hans van Eenennaam; Lorenzo Albertazzi; Tom F A de Greef
Journal:  J Am Chem Soc       Date:  2021-06-28       Impact factor: 15.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.